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Plasminogen activator inhibitor-1 (PAI-1), the primary inhibitor of tissue-type plasminogen activator and
urokinase, is known to convert readily to a latent form
by insertion of the reactive center loop into a central
b-sheet. Interaction with vitronectin stabilizes PAI-1
and decreases the rate of conversion to the latent form,
but conformational effects of vitronectin on the reactive
center loop of PAI-1 have not been documented. Mutant
forms of PAI-1 were designed with a cysteine substitution at either position P1* or P9 of the reactive center
loop. Labeling of the unique cysteine with a sulfhydrylreactive fluorophore provides a probe that is sensitive
to vitronectin binding. Results indicate that the scissile
P1–P1* bond of PAI-1 is more solvent exposed upon interaction with vitronectin, whereas the N-terminal portion of the reactive loop does not experience a significant change in its environment. These results were
complemented by labeling vitronectin with an argininespecific coumarin probe which compromises heparin
binding but does not interfere with PAI-1 binding to the
protein. Dissociation constants of approximately 100 nM
are calculated for the vitronectin/PAI-1 interaction from
titrations using both fluorescent probes. Furthermore,
experiments in which PAI-1 failed to compete with heparin for binding to vitronectin argue for separate binding sites for the two ligands on vitronectin.

The adhesive glycoprotein, vitronectin, circulates in human
plasma at concentrations of 200 – 400 mgzml21 and serves as a
regulatory protein in humoral defense mechanisms by interacting with macromolecules in the reaction cascades of coagulation and fibrinolysis (reviewed in Refs. 1–3). The circulating
form of vitronectin is a monomer of 72 kDa, and vitronectin is
also found in a multimeric form in platelet releasates and in
the extracellular matrix (4 – 6). The anti-fibrinolytic protein,
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The abbreviations used are: PAI-1, plasminogen activator inhibitor-1; tPA, tissue-type plasminogen activator; NBD, N,N9-dimethyl-N(acetyl)-N9-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine;
IANBD, iodoacetamide NBD; S338C, recombinant PAI-1 with cysteine

itor of tissue-type plasminogen activator and urokinase-type
plasminogen activator (7–11, reviewed in Refs. 12, 13). Like
other serpins, PAI-1 has a reactive center loop that mimics the
substrate of its target proteases (14, 15). The active conformation of PAI-1 is relatively unstable, so that the protein undergoes rapid conversion to a latent conformation which is characterized by the insertion of the reactive center loop into a
central b-sheet within the molecule (16). Interactions between
strands of the b-sheet and the reactive loop stabilize this conformation relative to the active conformation, in which the loop
is thought to protrude from the surface of the molecule (7, 16).
Binding to vitronectin results in a 2–3-fold increase in the
half-life of active PAI-1 (17–19). In addition to stabilizing the
active conformation of PAI-1, vitronectin also alters the protease specificity of the serpin so that the vitronectinzPAI-1 complex is endowed with the additional ability to inhibit thrombin
(20, 21). A vitronectin-binding site has been localized on the
surface of PAI-1 using site-directed mutagenesis (22) and
monoclonal antibodies (23). Binding of vitronectin is thought to
restrict the movement of the central b-sheet in PAI-1 by interactions that bridge the b-sheet and adjacent secondary structural elements and thus prevent insertion of the reactive center
loop (22). Based on the observation that vitronectin alters
PAI-1 protease specificity, it can be hypothesized that
vitronectin binding causes conformation changes in the reactive center loop as well. Fa et al. (24) have demonstrated that
vitronectin binding causes a decrease in the anisotropy and
increased rotational freedom of fluorescent reporters incorporated into the reactive center loop of PAI-1. Other details of
the vitronectin-induced conformational changes in PAI-1 are
uncharacterized.
Very little is known about concomitant changes that occur in
vitronectin when it interacts with the serpin. Moreover, there
is considerable debate in the literature regarding the PAI-1binding site(s) in vitronectin (reviewed in Ref. 25). Reports
utilizing synthetic peptides or proteolytic fragments do not
agree, with some results localizing the PAI-1-binding site to the
heparin-binding sequence located near the C terminus of
vitronectin (26 –30), others to the N-terminal somatomedin B
region (31–34), and yet another to a polypeptide consisting of
residues 115–121 from vitronectin (35). More recent work utilizing heterologous expression systems has focused on the somatomedin B domain of vitronectin, which contains eight cysteines thought to form a “disulfide knot” at the N terminus of
substituted for serine 338; M347C, recombinant PAI-1 with cysteine
substituted for methionine 347; NBDP19PAI-1, M347C mutant form of
PAI-1 labeled with NBD; NBDP9PAI-1, S338C mutant form of PAI-1
labeled with NBD; HOCGO, 7-hydroxycoumarinyl-3-glyoxal; HOCGOVN, vitronectin labeled with HOCGO; PEG, polyethylene glycol; BSA,
bovine serum albumin; HRP, horseradish peroxidase.
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Conformational Changes in PAI-1 and Vitronectin
vitronectin. Segments of the N-terminal somatomedin B domain expressed as fusion proteins with the maltose-binding
protein in Escherichia coli were shown to bind and stabilize the
active conformation of PAI-1 (33). In order to localize sequences
critical for PAI-1 binding, Deng et al. (34) generated chimeras
between segments of the vitronectin somatomedin B domain
and complementary sequences in other inactive somatomedin
B homology domains. These studies indicated that the essential
PAI-1 binding determinant was located between residues 12
and 30 of vitronectin, and alanine scanning mutagenesis revealed that all 8 cysteines and Gly-12, Asp-22, Leu-24, Tyr-27,
Tyr-28, and Asp-34 are essential to maintain PAI-1-binding
activity (34).
To gain further insight into the structural changes that occur
in both vitronectin and PAI-1 as they interact, and to understand more thoroughly the structural requirements for the
interaction, a strategy has been employed for following the
conformational changes in the molecules using fluorescent reporter groups. With site-directed mutagenesis, cysteines have
been engineered into positions P19 and P9 of the reactive center
loop in PAI-1, and the mutant proteins have been labeled with
the sulfhydryl-reactive probe, IANBD (36, 37). Since wild type
PAI-1 contains no cysteines, these fluorescent probes can be
exploited to obtain information about the local environment of
the reactive center loop at these positions. This work extends
the studies of Fa et al. (24) by evaluating probes at different
sites within the reactive center loop and evaluating whether
conformational changes are associated with increased or decreased solvent exposure of the probe. Also, a parallel experimental approach was taken in which an arginine-reactive coumarin derivative (38) was used for site-specific labeling of the
arginine-rich heparin-binding region of vitronectin.
Fluorescence spectroscopy of the labeled protein derivatives
has been used to gain insight into the interaction of intact
vitronectin and PAI-1 in solution. The following questions were
of interest and guided these studies. Is the conformation of the
reactive center loop of PAI-1 altered upon interaction with
vitronectin? Does binding of monomeric and multimeric forms
of vitronectin result in similar changes in the reactive center
loop of PAI-1? Can the heparin-binding domain of vitronectin
be preferentially labeled with an arginine-specific coumarin
derivative? Are there conformational changes in vitronectin
that are induced by interaction with PAI-1? Do PAI-1 and
heparin share a common binding determinant in vitronectin?
EXPERIMENTAL PROCEDURES

Materials—The fluorescent probe NBD was obtained from Molecular
Probes. Heparin purified from porcine mucosa grade 1-A was obtained
from Sigma. Murine monoclonal antibodies directed against human
vitronectin were obtained from Quidel. Rabbit anti-PAI-1 antiserum
was a generous gift of Dr. Daniel Lawrence, Holland Laboratory, American Red Cross, Rockville, MD. Polyclonal antiserum made in rabbit
against human vitronectin was obtained from Rockland Laboratories.
Peroxidase-linked goat anti-rabbit IgG was obtained from Vector Laboratories. All other reagents were of the highest grade commercially
available and were used without further purification.
Vitronectin was purified from human plasma by a modification of the
original protocol of Dahlback and Podack (39), as described by Bittorf et
al. (40). The purity of the protein was assessed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis under reducing conditions
followed by Coomassie staining (41). The molecular weight of vitronectin is 72,000, and the protein concentration was calculated using an
extinction coefficient of 1.02 mlzmg21zcm21 at 280 nm (42). Multimeric
vitronectin was prepared by incubating plasma-purified vitronectin
with 8 M urea overnight at room temperature, and the denaturant was
removed by extensive dialysis into PBS (0.05 M phosphate, pH 7.4,
containing 0.15 M NaCl and 1 mM EDTA) (42, 43). Vitronectin was
stored at 4 °C until use. Wild type recombinant PAI-1 was purified from
E. coli strains engineered to overexpress the protein (generously provided by Dr. David Ginsburg, Howard Hughes Medical Institute, Uni-
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versity of Michigan Medical Center, Ann Arbor), essentially as described by Lawrence et al. (7). PAI-1 purified from cells expressing the
protein was separated into its active and latent components using the
protocol determined by Kvassman and Shore (44). Recombinant forms
of PAI-1 with cysteine substituted for serine 338 (S338C) or cysteine
substituted for methionine 347 (M347C) were prepared as described in
Shore et al. (37).
Fluorescent Labeling of S338C and M347C—The protocol for labeling
and quantifying the P19 and P9 PAI-1 mutants has been described
previously (37). Briefly, concentrated samples of the purified proteins
were applied to a PD-10 gel filtration column (Bio-Rad) that had been
equilibrated with 0.05 M sodium phosphate, pH 6.6, containing 0.15 M
NaCl, 1 mM EDTA, 0.01% (v/v) Tween 80, and 150 mM IANBD. The
sample was allowed to react for 8 h at 25 °C in the dark. Fractions
containing PAI-1 were pooled and applied to a Sephadex G-25 superfine
column (Pharmacia Biotech, Inc.) to separate the protein from free dye.
Labeling stoichiometry was determined using absorbance measurements made at 280 and 497 nm in 0.1 M Tris-HCl, pH 8.5, containing 6
M guanidine and 1 mM EDTA. Extinction coefficients of 26,000 and
43,000 M21 cm21 were used to calculate the concentrations of NBD label
and PAI-1, respectively. A correction factor of 0.103 (e280/e497) was used
to correct the 280-nm absorbance of the labeled PAI-1 for the contribution of NBD (37). Samples were stored frozen at 220 °C until use.
Fluorescent Labeling of Human Vitronectin—The arginine-reactive
probe, hydroxycoumarin glyoxal (HOCGO) was prepared as described
by Baburaj et al. (38). Vitronectin (2 mM) was mixed with 10 mM HOCGO
in 50 mM HEPES, pH 7.5, containing 1 mM sodium borate. The reaction
was allowed to proceed in the dark at room temperature for 16 h. Borate
and unreacted probe were separated from the protein by gel filtration
on a Sephadex G-25 column (Pharmacia Biotech, Inc.), equilibrated in
50 mM HEPES, pH 7.5. EDTA was added to a final concentration of 1
mM for storage of the sample at 4 °C. The labeling stoichiometry was
determined spectrophotometrically at 374 nm using an extinction coefficient of 14,200 M21 cm21. Protein concentration was determined using
a bicinchoninic acid assay (Pierce). The same protocol was used to label
vitronectin in the presence of 0.4 mM heparin.
Fluorescence Measurements—Changes in the fluorescence emission/
excitation ratio of NBD at the P19 and P9 positions of PAI-1 were
measured using an SLM 8000 spectrofluorimeter with the excitation
monochromator set at 480 nm and the emission wavelength set for 540
nm. Excitation and emission slits were set at 4 and 8 mm, respectively.
Solutions of NBD-P19 PAI-1 (490 nM) in 0.1 M HEPES, pH 7.4, containing 0.1 M NaCl, 1 mM EDTA, and 0.1% (w/v) PEG-8000 were titrated
with small volume aliquots from a stock of purified human vitronectin
(8 –30 mM) to a final concentration of 1.25 mM. Reactions were performed
in a total volume of 2.0 ml in acrylic cuvettes (Sarstedt) that were
previously coated with a 1.0% (w/v) solution of PEG-20,000, according to
the procedure of Latallo and Hall (45). A quench in fluorescence was
observed that was dependent on manipulation of the sample and was
possibly due to adsorption of the PAI-1 onto the surfaces of the cuvette
and pipette tips. To correct for this quench, duplicate titrations were
always performed. Vitronectin was added to the NBD-PAI-1 solution in
one cuvette. To an identical sample in the other cuvette, equal volumes
of buffer were added to obtain the F0 values. The data were then
normalized using the equation (F 2 F0)/F0, where F is the ratio of
emission/excitation intensities at each vitronectin addition, and F0 is
the emission/excitation ratio of NBD-P19 PAI-1 in the absence of added
vitronectin. Scans were performed over a wavelength range of 500 – 600
nm using an excitation wavelength of 480 nm.
The interaction between HOCGO-VN and PAI-1 was analyzed by
measuring changes in the fluorescence intensity of the coumarin-derived probe upon interaction with wild type PAI-1. A Perkin-Elmer
LS50B luminescence spectrometer with the excitation monochromator
set at 335 nm was used to measure fluorescent intensity of HOCGO-VN
at 453 nm, the emission maximum of HOCGO-VN. The reaction was
performed in a 1.0-ml quartz cuvette (Hellma) in 0.1 M HEPES, pH 7.4,
containing 0.1 M NaCl, 1 mM EDTA, and 0.1% (w/v) PEG-8000.
HOCGO-VN (290 nM) was titrated by addition of small volume aliquots
of active wild type PAI-1 (26 mM stock) to a final concentration of 1.6 mM.
The data were corrected for dilution and normalized using the relationship (F 2 F0)/F0, where F is the emission at each PAI-1 addition and F0
is the emission of HOCGO-VN in the absence of PAI-1.
For both measurements the (F 2 F0)/F0 was plotted as a function of
titrant concentration using Kaleidagraph software and fit to Equation
1 describing the binding isotherm to obtain the Fmax and Kd (46):
DF 5 DFmax/2R*~R 1 T 1 Kd 2 ~~R 1 T 1 Kd!2 2 4TR!1/2!

(Eq. 1)
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where DF is the change in fluorescence (F 2 F0)/F0, R is the total
concentration of fluorescent protein, T is the total titrant concentration,
Kd is the dissociation constant, and Fmax is the fluorescence at saturating concentrations of titrant.
Iodide Quenching Studies—For iodide quenching studies, solutions
of 130 nM HOCGO-VN (prepared in the presence or in the absence of 0.4
mM heparin) in 50 mM HEPES, pH 7.5, were titrated with 5 M NaI,
prepared in the same buffer. Using an excitation wavelength of 335 nm,
the fluorescence emission of the labeled protein was measured at 453
nm after each addition of NaI (47). Likewise, the extent of iodide
quenching of the coumarin-derived probe on HOCGO-VN was measured in the absence and presence of saturating concentrations of PAI-1.
A 130 nM solution of HOCGO-VN in 0.1 M HEPES, pH 7.4, containing
0.1 M NaCl, 1 mM EDTA, and 0.1% (w/v) PEG-8000 was titrated with
NaI to a final concentration of 480 mM (47). A similar quenching
experiment was performed after the addition of 1.1 mM PAI-1 to a
vitronectin solution (130 nM). Fluorescence emission measurements
were made after each addition of iodide, as described above.
Measurements of Vitronectin Binding to PAI-1 in Microtiter Dishes—
Interactions between recombinant wild type PAI-1 and HOCGO-VN or
unmodified vitronectin were measured using a slight modification of
the competitive binding assay described by Seiffert and Loskutoff (31).
Briefly, microtiter plates were coated with 50 ml of a 1 mgzml21 solution
of native human vitronectin at 4 °C for 16 h. After washing the plates
three times with PBS, the wells were blocked with 200 ml of 3.0% (w/v)
BSA in PBS at 37 °C for 1 h. The wells were washed three times with
PBS/Tween/BSA (PBS containing 0.1% BSA (w/v) and 0.1% Tween 20
(v/v)) after this and all subsequent incubation steps. Serial dilutions of
vitronectin (3 mgzml21 to 0.0003 mgzml21) in PBS/Tween/BSA were
added to the plates and mixed with 0.4 nM PAI-1 to give a final PAI-1
concentration of 0.2 nM in 100 ml. Polyclonal anti-PAI-1 antibodies
diluted 1:10,000 in PBS/Tween/BSA, followed by HRP-linked goat antirabbit IgG (1:1000) were used to detect bound PAI-1. The plates were
developed with a 0.2 mgzml21 solution of 2,29-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) in 50 mM sodium citrate, pH 5.5, containing
a 1:2000 dilution of 30% hydrogen peroxide. The extent of PAI-1 binding
was determined by measuring the absorbance at 405 nm in a Microtek
microplate reader. Several absorbance readings were performed over
time after addition of substrate to ensure that data were in the linear
range of the assay.
The effect of heparin on the vitronectinzPAI-1 interaction was determined by preincubating serial dilutions of vitronectin with 0, 0.4, 4.0,
and 40 mM heparin before adding it to PAI-1 in the above assay. Also, a
noncompetitive PAI-1 binding assay which measures PAI-1 binding to
solid phase vitronectin was performed. In this experiment, PAI-1 was
serially diluted and added to vitronectin-coated plates in the presence
or absence of 0.5 mgzml21 heparin. PAI-1 binding was detected and
quantified as described above.
Heparin Binding Immunoassay—The effect of PAI-1 on the vitronectin/heparin interaction was analyzed using an assay that measures
protein binding to heparin-coated microtiter plates. For coating, a
100-ml solution of heparin (1.0 mgzml21 in 50 mM sodium carbonate, pH
9.6) was incubated in microtiter wells for 16 h at 4 °C. The plates were
washed three times with PBS/casein/Tween (PBS containing 0.1% (w/v)
casein and 0.1% (v/v) Tween 20) after this and all other incubation
steps. Nonspecific binding was prevented using a blocking solution of
PBS containing 0.03% casein (w/v) and 0.05% (v/v) Tween 20. After
blocking, the plates were incubated with serial dilutions of vitronectin
in the presence or absence of 0.6 mM PAI-1 for 2 h at 37 °C. The plates
were probed for vitronectin binding using polyclonal anti-vitronectin
(1:5000) followed by goat anti-rabbit IgG conjugated to HRP (1:1000).
Duplicate plates were also probed for PAI-1 binding using polyclonal
anti-PAI-1 (1:10,000) followed by HRP-linked goat anti-rabbit IgG. All
dilutions were made in PBS/casein/Tween. The amount of bound protein was quantified by developing and measuring the absorbance at 405
nm as described above.
PAI-1 Activity Assay—Kinetic assays were designed to measure the
rate at which PAI-1 converts to the latent form by measuring the
concentration of active PAI-1 at any given time by its ability to inhibit
urokinase. PAI-1 (0.48 mM final concentration) was incubated for varying periods at 37 °C in a buffer of 25 mM HEPES, pH 7.4, containing 50
mM NaCl, 0.01% (w/v) BSA, and 1.3 mM EDTA. A reaction was performed in parallel, with coumarin-labeled vitronectin added to the
PAI-1 sample in a final concentration of 0.5 mM. Aliquots (50 ml) of PAI-1
or the PAI-1/vitronectin mixture were removed at intermediate times
up to 8 h and were assayed for remaining PAI-1 activity by incubating
with 0.1– 0.2 mM urokinase in 200 ml of 0.1 M HEPES, pH 7.4, containing
0.15 M NaCl, 1 mM EDTA, 0.1% (w/v) PEG-8000, and 0.2% (w/v) BSA.

FIG. 1. Crystal structures that represent models for latent and
active serpins. Ribbon diagrams of latent PAI-1 and ovalbumin were
generated using the Insight program on a Silicon Graphics workstation.
Coordinates from the x-ray crystal structures of the two proteins (20,
52) were used. b-Sheet A is visible on the surface of latent PAI-1 and
has been identified as a vitronectin-binding site. The reactive center
loop is shown in blue. In the active form of PAI-1, the reactive center
loop is thought to be an exposed loop extending from the b-sheet on the
surface of the protein, similar in structure to the homologous region
shaded in blue in the ovalbumin structure. Amino acids depicted in the
green and yellow space-filling models represent the P19 and P9 positions, respectively. Note that the P19 and P9 residues are located within
the exposed reactive center loop in the model for the active structure,
and these two amino acids are buried within the hydrophobic core of the
protein in the latent form of PAI-1.
After a 30-min incubation of PAI-1 or the PAI-1zvitronectin complex
with urokinase at room temperature, residual urokinase activity was
measured by hydrolysis of the chromogenic substrate, S-2444 (KabiHepar, Pharmacia).
RESULTS

A Fluorescent Probe in the Reactive Center Loop of PAI-1 Can
Be Used to Detect Vitronectin-induced Conformational Changes—Recombinant forms of PAI-1 with M347C and S338C mutations at the P19 and P9 positions of the reactive center loop
(36, 37), respectively, were expressed in E. coli and purified.
Using the sulfhydryl-specific fluorophore, IANBD, the unique
cysteines in the two proteins were fluorescently labeled at a 1:1
stoichiometry. Fig. 1 shows ribbon diagrams derived from the
crystal structures of latent PAI-1 (16) and of ovalbumin (48), a
serpin-like molecule thought to exhibit structural features resembling the active conformation of PAI-1. The green and yellow space-filling symbols in the diagram denote the positions of
the NBD probe at the P19 and P9 positions, respectively. The
activity of both mutant forms of PAI-1 was comparable with
that exhibited by the wild type protein (36, 37). The fluorescence of the labeled proteins was monitored as the NBD-PAI-1
mutants were titrated with native human vitronectin.
Vitronectin binding resulted in a 10% quench in the fluorescence of the probe at the P19 position of the reactive center loop.
Fig. 2A shows the spectra of NBDP19PAI-1 in the presence and
absence of saturating vitronectin. When NBDP19PAI-1 was
titrated with vitronectin, a dissociation constant of 100 6 50 nM
was obtained (Fig. 2B). These data indicate that vitronectin
induces a conformational change in the reactive center loop of
PAI-1 that shifts the probe at the scissile bond into a somewhat
more hydrophilic milieu. In contrast, no fluorescence changes
were detected when NBDP9PAI-1 was titrated with vitronectin
(Fig. 2B).
Native and Multimeric Vitronectin Differ in Effects on the

Conformational Changes in PAI-1 and Vitronectin
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FIG. 3. Fluorescence emission spectra of HOCGO-modified
vitronectin. Native vitronectin (2 mM) was labeled with a 5:1 molar
ratio of hydroxycoumarin glyoxal to protein in the presence and absence
of added heparin as described under “Experimental Procedures.” The
fluorescence emission spectra of the labeled products produced in the
absence (solid line) and presence (dashed line) of heparin added to a 0.4
mM concentration are shown. The excitation wavelength was 335 nm.

FIG. 2. Fluorescence changes in NBDP1*PAI-1 upon interaction with vitronectin. A shows the fluorescence emission spectrum
(excitation wavelength 5 480 nm) for a 490 nM solution of
NBDP19PAI-1 in the presence (dashed line) and absence (solid line) of
native vitronectin added to a 1.3 mM final concentration. B shows
binding isotherms for the interaction between NBDP19PAI-1 and native
vitronectin (●), NBDP19PAI-1 and multimeric vitronectin (E), and
NBDP9 PAI-1 with native vitronectin (å). Fluorescence intensity, using
an excitation wavelength of 480 nm and an emission wavelength of 540
nm, was recorded following each addition of vitronectin. The data for
native vitronectin interacting with NBDP19PAI-1 (●) were analyzed as
described in “Experimental Procedures” to generate the binding isotherm shown with the solid line.

Scissile Peptide Bond in PAI-1—Interpretation of previous
studies on the interaction between PAI-1 and vitronectin have
been complicated by the fact that vitronectin, like PAI-1, exists
in an alternative form. Although vitronectin purified from
plasma exists as a monomer with a molecular weight of 72,000
(42), the glycoprotein is found as a high molecular weight
species in the extracellular matrix and in platelet releasates
(4 – 6). Multimeric vitronectin which is produced in vitro has
been characterized extensively and is considered to be the
product of an alternative folding pathway (6, 40, 42, 43). Potential differences between PAI-1 binding by the native and
multimeric forms of vitronectin are not clear, although multimeric vitronectin may have a higher capacity for PAI-1 binding
when bound to a solid phase (30). It has been demonstrated
that vitronectin in the extracellular matrix stabilizes the active
conformation of PAI-1 almost 10-fold (49), a much higher degree of stabilization than is observed with plasma-derived
vitronectin. While many reports indicate that multimeric forms
of vitronectin are capable of binding PAI-1 (17, 30), the binding
of multimeric vitronectin is contrasted with native vitronectin
since it does not alter PAI-1 substrate specificity (21). The data

in Fig. 2B indicate that the multimeric form of vitronectin did
not alter the fluorescence of NBDP19PAI-1. Thus, multimeric
vitronectin does not alter the conformation of the reactive center loop at the scissile bond of PAI-1 in the same manner as
does native vitronectin, providing separate evidence for differential effects of the two forms of vitronectin on the reactive
center loop of the inhibitor.
Heparin Binding Protects Exposed Arginines from Modification with Hydroxycoumarin Glyoxal—The sequence spanning
residues 341–378 near the C terminus of vitronectin has been
identified as the heparin-binding determinant (28, 50) and as a
putative PAI-1-binding site (26 –30). The region contains 7 of
the 35 arginine residues found within vitronectin and fits the
heparin-binding consensus sequence described by Cardin and
Weintraub (51) and Sobel et al. (52). The novel arginine-reactive fluorescent probe, hydroxycoumarin glyoxal (38), was exploited with the goal of preferentially labeling the arginine-rich
heparin-binding domain of vitronectin with an environmentally sensitive reporter group. Native vitronectin was treated
with the HOCGO probe under mild reaction conditions favoring a low labeling stoichiometry. Unreacted probe was removed
from the protein by gel filtration, and the absorption and fluorescence spectra of the modified vitronectin were examined.
Fig. 3 shows the fluorescence spectrum of HOCGO-VN. The
labeling stoichiometry was found to be approximately 2 mol of
HOCGO per mol of vitronectin.
In order to determine whether the probe was targeted to the
heparin-binding domain, studies were performed to assess the
effect of heparin on the labeling reaction. It was rationalized
that if the probe was preferentially incorporated into the glycosaminoglycan-binding domain, heparin binding would protect this arginine-rich sequence from labeling. The dashed line
in Fig. 3 represents the fluorescence spectrum of vitronectin
labeled in the presence of saturating concentrations of heparin.
Although fluorescence from the coumarin probe is detected in
the vitronectin sample labeled in the presence of heparin, the
fluorescence intensity is significantly diminished in comparison to the coumarin probe incorporated into vitronectin upon
labeling in the absence of heparin. The decreased fluorescence
intensity correlates with decreased labeling, supporting the
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FIG. 4. Stern-Volmer plots for iodide quenching of HOCGOVN. HOCGO-VN prepared in the absence (●) and presence (E) of
heparin added in saturating concentrations was titrated with 5 M NaI.
Data are plotted as Stern-Volmer quenching curves, with F0/F plotted
on the y axis against the molar concentration of iodide on the x axis. F0
represents the initial fluorescence of the sample prior to addition of NaI,
and F represents the fluorescence intensity at a given concentration of
iodide. Fluorescence emission at 453 nm was measured after each
addition of iodide.

hypothesis that heparin competes with the coumarin label for
binding to the heparin-binding site in vitronectin.
To investigate further the localization of HOCGO within
vitronectin, iodide quenching studies were performed on the
vitronectin samples labeled in the presence or absence of added
heparin (Fig. 4). Such studies provide information about the
solvent accessibility of fluorescent moieties on proteins (47).
Vitronectin treated with HOCGO in the absence of heparin is
susceptible to quenching by iodide; however, the product of
labeling in the presence of heparin is not accessible to the
quencher. Together, these data indicate that two distinct species of modified vitronectin are generated when the protein is
treated with HOCGO in the absence or presence of added
heparin. The results suggest that surface-exposed arginines
react preferentially with coumarin glyoxal in the absence of
heparin. Conversely, in the presence of heparin, these arginines are protected from labeling, and arginine(s) that are less
exposed in uncomplexed vitronectin become modified. The observation that heparin protects labeling of certain arginines
infers that these residues are located within the heparin-binding region.
HOCGO-VN Displays Weakened Heparin-binding Activity—It was predicted that modification of arginines within the
glycosaminoglycan-binding domain should have a deleterious
effect on heparin binding. To determine whether incorporation
of the probe had disrupted heparin-binding determinants, interaction of heparin with HOCGO-VN was compared with that
of the unlabeled protein. To achieve the same level of heparin
binding, 10-fold higher concentrations of HOCGO-VN were
required compared with unmodified vitronectin (Fig. 5). These
data indicate that modification of arginine residue(s) disrupts
critical heparin-binding elements. Along with observations
that heparin protects exposed arginines from modification,
these data suggest that the fluorescent probes in HOCGO-VN
are incorporated into the heparin-binding domain of vitronectin. Studies are currently underway to identify the specific
arginines labeled with coumarin glyoxal.
HOCGO-modified Vitronectin Binds and Stabilizes PAI-1—

FIG. 5. Heparin binding immunoassays comparing modified
and unmodified vitronectin. Unlabeled native vitronectin (●) or
HOCGO-VN (E) was serially diluted in heparin-coated microtiter
plates. Bound vitronectin was detected with anti-vitronectin antibodies
as described under “Experimental Procedures.” Absorbance at 405 nm
(average of three measurements) is plotted versus the vitronectin concentration (mM) expressed on a logarithmic scale.

HOCGO-VN was tested for its ability to bind PAI-1. If heparin
and PAI-1 share the same binding determinants, a modification that weakens heparin binding would also be expected to
alter PAI-1 binding. HOCGO-VN was tested for the ability to
bind PAI-1 using a competitive binding assay in which PAI-1
was incubated with vitronectin-coated microtiter plates in the
presence of increasing concentrations of competing vitronectin
in solution (31). The fluorescently labeled vitronectin competed
effectively with immobilized, unmodified vitronectin for binding of PAI-1 (Fig. 6).
A direct consequence of vitronectin binding to PAI-1 is that
the half-life of the active conformation of the serpin is increased
2–3-fold (17–19). In order to test whether the arginine-modified
vitronectin could stabilize the serpin, PAI-1 was incubated
with HOCGO-VN, and the ability of PAI-1 to inhibit urokinase
was measured over time. As shown in Fig. 7, the activity of
PAI-1 in the absence of vitronectin decreases 50% within 1 h,
indicative of conversion of the serpin to its inactive, latent
form. When PAI-1 is incubated with HOCGO-VN, activity of
the serpin is stabilized considerably, with the half-life increasing to 6 h. This behavior reflects the PAI-1 stabilizing property
which has been well characterized with unmodified vitronectin
(17–19). Thus, while the fluorophore on HOCGO-VN weakens
heparin binding, it does not prevent PAI-1 binding or PAI-1
stabilization. From these results, it can be concluded that the
heparin-binding element on vitronectin that is disrupted by the
arginine-reactive fluor is not essential for binding or stabilizing
PAI-1.
PAI-1 Induces Conformation Changes in Vitronectin That
Lead to a Quench in the Fluorescence of the Coumarin Probe—
The arginine-reactive probe incorporated into vitronectin was
exploited for the purpose of detecting PAI-1-induced conformational changes in vitronectin. Fig. 8 demonstrates that the
emission of the fluor is quenched approximately 15% when
HOCGO-VN is complexed with PAI-1. When a 260 nM solution
of HOCGO-VN is titrated with PAI-1, a binding isotherm is
obtained which gives a Kd of 112 6 15 nM, a value that is in
excellent agreement with the dissociation constant for the
vitronectinzNBDP19PAI-1 reaction. The quench in fluorescence
suggests that when PAI-1 binds vitronectin, a conformational
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FIG. 6. PAI-1 binding activity of HOCGO-VN. HOCGO-VN (E)
was assayed for the ability to compete with immobilized unmodified
vitronectin for binding PAI-1. The binding activity of modified vitronectin is compared with the PAI-1 binding of unmodified vitronectin (●) in
the same assay. The absorbance of samples in wells containing PAI-1
and no competing vitronectin provided the value for 100% binding.
Percent binding inhibition was determined by subtracting the absorbance at each concentration of competing vitronectin from this value and
then dividing by the absorbance in the absence of competing
vitronectin.

FIG. 7. Kinetics of PAI-1 stabilization by HOCGO-VN. PAI-1 was
incubated at 37 °C in the presence (M) or absence (●) of HOCGO-VN for
periods up to 8 h to measure stabilizing effects of the vitronectin sample
on PAI-1 activity. At intermediate time intervals, remaining active
PAI-1 was determined by its ability to inhibit urokinase in a colorimetric assay, as described in “Experimental Procedures.”

change occurs such that the fluorescent probe is shifted somewhat to a more hydrophilic environment. In contrast, the addition of saturating concentrations of heparin did not induce
any changes in the fluorescence of the probe (data not shown),
a result which is not surprising since heparin binding to
HOCGO-VN is compromised.
PAI-1 Binding Does Not Protect the Coumarin Label on
Vitronectin from NaI Quenching—Alterations in the fluorescence of the coumarin probe upon PAI-1 binding could result
from direct interaction of PAI-1 in the vicinity of the coumarin
probe on vitronectin. Alternatively, conformational changes induced by PAI-1 binding to sites elsewhere in vitronectin could
result in changes in the fluorescence properties of the probe. To
determine which scenario was responsible for the changes in
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FIG. 8. Fluorescence changes in HOCGO-VN observed upon
interaction with PAI-1. Using an excitation wavelength of 335 nm
and emission wavelength of 453 nm, the fluorescence of a 260 nM
sample of HOCGO-VN was measured upon addition of varying amounts
of PAI-1 up to saturating concentrations. The data (●) were fit to a
binding equation to obtain the binding isotherm shown in the solid line.

the coumarin probe when PAI-1 binds, HOCGO-VN was titrated with NaI in the absence and presence of saturating
concentrations of PAI-1 (Fig. 9). If PAI-1 binding were to occur
at or near the site(s) where the protein has been labeled,
formation of complexes with PAI-1 would be expected to reduce
the accessibility to diffusible quencher. However, although
PAI-1 binds and is stabilized by HOCGO-VN, the serpin does
not confer protection from iodide quenching to the fluor (Fig. 9).
From these results, it is concluded that PAI-1 does not bind
HOCGO-VN in a way that masks the modified arginines or
greatly alters their degree of solvent exposure.2 Furthermore,
these data indicate that PAI-1 does not bind to the heparinbinding domain, as that would alter the quenching behavior of
the coumarin probe. PAI-1-induced conformational changes in
HOCGO-VN are manifested only in slight changes in the hydrophilic milieu of the probe. Although the measurement of a
15% quench in fluorescence upon formation of a complex between HOCGO-VN and PAI-1 (Fig. 8) indicates that there is an
increased exposure of the coumarin probe in the complex, its
accessibility to small diffusible quenchers is not greatly
affected.
Heparin and PAI-1 Do Not Compete for Binding Sites on
Vitronectin—A series of assays was performed to determine the
effect of heparin on the PAI-1zvitronectin interaction. If PAI-1
and heparin share the same binding site on vitronectin, heparin should inhibit PAI-1 from binding to vitronectin. In an
experiment in which vitronectin was adsorbed to a microtiter
plate and various concentrations of PAI-1 were added in the
presence or absence of heparin, it was found that heparin did
not inhibit and, in fact, slightly enhanced the interaction between PAI-1 and vitronectin (Fig. 10A). In a competitive assay,
2
In order to test for potential disruption of the PAI-1zvitronectin
complex at the higher ionic strengths achieved in the quenching experiment, salt effects on the interaction were determined by comparing the
binding of PAI-1 to immobilized vitronectin at 0.15 and 2 M NaCl. The
protocol for the non-competitive PAI-1 binding assay is described under
“Experimental Procedures.” From this analysis, there were no significant differences in the binding of PAI-1 to vitronectin at the two ionic
strengths tested. This is consistent with the observed lack of salt effects
on the PAI-1/vitronectin interaction reported by Sigudattor and Wiman
(66).
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FIG. 9. Stern-Volmer plot for iodide quenching of the HOCGOVNzPAI-1 complex. The fluorescence of the extrinsic probe on
HOCGO-VN (E) or the HOCGO-VNzPAI-1 complex (●) was titrated
with NaI as described under “Experimental Procedures.” The concentration of HOCGO-VN was fixed at 130 nM in both experiments, and the
HOCGO-VN complex was formed upon addition of PAI-1 to a final
concentration that equaled 1.1 mM PAI-1. The data were plotted as F0/F,
where F0 is the fluorescence in the absence of iodide and F is the
fluorescence at a given concentration of iodide.

vitronectin was immobilized and PAI-1 was incubated in the
presence of increasing concentrations of competing vitronectin
or vitronectin-heparin complexes. Again, heparin did not prevent PAI-1 binding to either the surface- immobilized vitronectin or to the competing vitronectin in solution (Fig. 10B). In a
final experiment, the effect of PAI-1 on the heparin-binding
activity of vitronectin was assessed. Increasing concentrations
of vitronectin or pre-formed vitronectinzPAI-1 complexes were
added directly to heparin-coated microtiter plates and assayed
for binding. The amount of vitronectin bound to heparin was
increased slightly when vitronectin was allowed to form complexes with PAI-1 prior to being added to the heparin-coated
plate (Fig. 10C). Although a quantitative analysis of these
experiments is complicated by the fact that heparin binds both
PAI-1 and vitronectin, the results from this series of experiments clearly indicate that PAI-1 and heparin do not compete
for binding to vitronectin.
DISCUSSION

Vitronectin has been found to associate with PAI-1 in vivo
and has been shown to stabilize its active conformation (17–
19). The stabilization of PAI-1 that occurs as a result of binding
to vitronectin represents a regulatory factor in the cascade of
reactions that control fibrinolysis. In fact, vitronectin directs
PAI-1 activity through three separate mechanisms as follows:
1) vitronectin stabilizes the active conformation of PAI-1 (17–
19); 2) it alters the protease specificity of the serpin (20, 21);
and 3) it may help maintain a distribution between PAI-1 in
plasma and the extracellular matrix, where vitronectin is
found in native and multimeric forms, respectively (53).
Elucidation of the conformational changes and requirements
associated with the interaction of PAI-1 and vitronectin has
been complicated by the propensity of both molecules to exist in
alternative conformations. Moreover, the methods traditionally
used to study this interaction have involved harsh treatments
of the proteins, which are likely to have altered their conformations, or proteolytic fragments, which have different binding
characteristics compared with the native molecules. The objec-

FIG. 10. Assays to distinguish independent versus competitive
binding of heparin and PAI-1 to vitronectin. A, serial dilutions of
PAI-1 were incubated with surface-immobilized vitronectin in the absence (●) or presence (E) of heparin, and bound PAI-1 was detected
immunochemically as described under “Experimental Procedures.” Assays were performed using conditions in which the absorbance shows a
linear relationship with the amount of PAI-1 bound to vitronectin. B,
the effect of heparin on a competitive PAI-1-binding assay was determined as described under “Experimental Procedures.” The percent inhibition of PAI-1 binding observed at various concentrations of vitronectin is shown. The assays were performed in the presence of 0 (●), 0.4
(E), 4.0 (å), and 40 mM heparin (Ç). C, the effect of PAI-1 on the
interaction between vitronectin and heparin was determined by incubating various concentrations of vitronectin in microtiter plates coated
with 1 mgzml21 heparin. Serial dilutions of vitronectin in buffer alone
(●) or in a solution containing 0.6 mM PAI-1 (E) were tested in the assay
for effective binding to the heparin-coated plates.

tive of this study was to develop a method for analyzing structural aspects of the PAI-1zvitronectin interaction under conditions that maintain the proteins in their native conformation.
Fluorescent probes targeted to specific regions of the proteins
were exploited to monitor conformational changes that occur as
PAI-1 and vitronectin interact. These results are discussed in
response to the questions posed in the introduction.
Conformational Changes in the Reactive Center Loop of
PAI-1 Are Associated with Vitronectin Binding—To determine
the effects of vitronectin binding on the reactive center loop, the
fluorescent probe, NBD, was reacted with the unique sulfhydryl group in each of two mutant forms of PAI-1, M347C and
S338C. The two sites of labeling provide environmentally sensitive probes at the P19 and P9 positions of the reactive center
loop, respectively. The usefulness of these probes to detect
conformational changes in the reactive center loop of PAI-1 was
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demonstrated previously by Shore et al. (37). In those studies,
the fluorescence of NBDP9PAI-1 was found to be enhanced
upon conversion to latency or upon complex formation with
tPA, consistent with burial of the probe within the hydrophobic
core of the protein. In the present studies, vitronectin binding
induced a 10% decrease in probe fluorescence at the P19 position, but a corresponding fluorescence change at the P9 position was not observed. The fluorescence change at the P19 site
is as expected for movement of the probe at the scissile bond to
a slightly more hydrophilic milieu.
The results demonstrate that a conformational change at the
scissile bond in the reactive center loop is associated with
vitronectin binding. In serpins, protease specificity is determined by the primary sequence and conformation of the reactive center loop. Lawrence et al. (54) have shown that the
substrate specificity of PAI-1 can be altered by substitutions in
the reactive center loop based on the sequences of other serpins
(20, 54). Other studies have indicated that the P1 residue of the
scissile bond in PAI-1 is critical for both substrate specificity
and activity against tPA (55–57). A methionine to arginine
substitution at this position renders PAI-1 inactive against tPA
but active against thrombin (57). It has also been reported that
vitronectin restores the tPA inhibitory activity of this mutant
form of PAI-1 (57). This conclusion is consistent with the observation in this work that vitronectin induces changes in the
conformation of PAI-1 within the reactive center loop. The data
from the present studies are the first to indicate that vitronectin induces local changes in the vicinity of the scissile bond,
rather than changes that affect the entire reactive center loop.
This study and that of Fa et al. (24) are significant in demonstrating that subtle changes in the conformation of the loop
affect the specificity toward target proteinases.
The affinity of the interaction between vitronectin and PAI-1
is high. Reports of the Kd vary from 0.1 to 190 nM (18, 21, 22,
58). Furthermore, some differences in the binding affinity between native and multimeric vitronectin have been suggested
(21, 30). The wide range in estimates of affinity of vitronectin
for PAI-1 is surprising and may be attributed in part to the
conformational lability of both proteins. The result is that
different forms of both proteins, including active and latent
forms of PAI-1, as well as monomeric and multimeric forms of
vitronectin, have not always been distinguished in binding
assays. Furthermore, previous estimates of the Kd have relied
on kinetic and Scatchard analyses of PAI-1 binding to immobilized vitronectin or vitronectin binding to immobilized PAI-1
(18, 22, 58). It is difficult to accurately determine Kd values
with these solid phase methods, because one must assume a
concentration for the immobilized protein and one must also
assume that binding sites are accessible. In fact, vitronectin
has been shown to lose b-sheet structure upon adsorption to
plastic (59). Moreover, Deng et al. (25) have observed that the
vitronectin-binding site in PAI-1 is disrupted when the serpin
is immobilized. Estimates of the Kd for the interaction based on
ligand binding directly to immobilized proteins, therefore, may
not accurately reflect the Kd of the interaction in solution.
The Kd values determined for the interaction of native
vitronectin and PAI-1 in this study, using fluorescently labeled
forms of either protein, were estimated to be equal to or lower
than 100 nM. These represent the first determinations of the
affinity of the interaction between the two proteins in solution.
This approach obviates difficulties with the solid phase methods, providing a more reliable estimate of the energetics of
interaction between vitronectin and PAI-1. It should be noted
that these experiments were performed at protein concentrations (200 – 400 nM) that exceed the estimates for the Kd. Attempts were made to reduce the concentration of receptor pro-
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tein; however, the low fluorescent yield from the labels and loss
of protein due to adsorption precluded further analyses. Other
methods that are more sensitive to binding interactions in the
required concentration range (1–50 nM) are being pursued in
this laboratory.
Binding of Native or Multimeric Vitronectin to PAI-1 Does
Not Lead to Identical Changes in the Conformation of the Reactive Center Loop—PAI-1 originally purified from denatured
plasma was found to co-purify with vitronectin in a complex of
450 kDa (17). That both multimeric and native vitronectin bind
PAI-1 is clearly established (17, 30, 35); however, it is unclear
whether both forms of vitronectin have the same effect on
PAI-1 conformation. Indeed, the different forms of vitronectin
have diverse effects on PAI-1 activity. Stabilization of PAI-1 by
the extracellular matrix, where vitronectin is found in its multimeric conformation, is significantly higher than the stabilization of PAI-1 by purified plasma vitronectin. Unlike native
vitronectin, multimeric vitronectin does not alter PAI-1 substrate specificity (21). Also, it has been reported that native,
but not multimeric, vitronectin can enhance the PAI-1-induced
cellular clearance of thrombin by low density lipoprotein
receptors (60).
To assess whether multimeric PAI-1 causes conformational
changes in the reactive center loop of PAI-1, the fluorescence of
NBDP19PAI-1 was measured upon addition of multimeric
vitronectin. This form of vitronectin did not alter the fluorescence of the probe, suggesting that the conformation at the
scissile bond is not affected by PAI-1 binding to multimeric
vitronectin. These data imply that the contrasting effects of
native and multimeric vitronectin on the substrate specificity
of PAI-1 result, at least in part, from differential effects of the
two molecules on the conformation at the scissile bond.
An Arginine-specific Probe, Hydroxycoumarin Glyoxal, Is
Targeted to the Heparin-binding Region of Vitronectin—The
conformation of the heparin-binding sequence in vitronectin
has been the subject of a great deal of discussion in the literature. Observations that vitronectin in denatured plasma binds
heparin more efficiently than native vitronectin (61, 62) resulted in the hypothesis that the heparin-binding domain is
buried in the native molecule (62– 64). Conformational changes
induced by treatments with chaotropic agents, ligands, heat, or
acid were thought to expose the heparin-binding domain (6, 40,
42, 43, 64, 65). A recent study by Zhuang et al.3 provided
evidence that the heparin-binding domain of vitronectin is not
buried in the native state of the molecule and that apparent
differences in affinity between native and multimeric vitronectin are due to differences in binding valency and are not the
result of increased exposure of the heparin-binding domain.
Based on this observation, it was hypothesized that an arginine-selective fluorescent probe might be preferentially targeted to the arginine-rich heparin-binding domain of vitronectin. The product could then serve as an agent for monitoring
PAI-1-induced changes in the heparin-binding region of
vitronectin. When treated with hydroxycoumarin glyoxal,
vitronectin was labeled at a stoichiometry of approximately 2
mol of probe per mol of protein. Further analysis revealed that
HOCGO-VN bound heparin more weakly than unlabeled
vitronectin. Including heparin during the labeling reaction resulted in protection of a set of arginines from labeling. Together, these data provide evidence that the heparin-binding
domain of vitronectin serves as a target for the arginine-reactive probe. Peptide mapping of the labeled protein will be
required to identify the exact location of the probe(s) among the
seven arginine residues within the heparin-binding domain.

3

P. Zhuang, T. Chen, and C. B. Peterson, submitted for publication.
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PAI-1-induced Conformational Changes in Vitronectin Can
Be Detected Using the HOCGO-labeled Protein—Coumarinmodified vitronectin provided a tool for analyzing conformational changes in vitronectin associated with PAI-1 binding.
HOCGO-VN competed effectively with immobilized vitronectin
for PAI-1 binding. The HOCGO-VN behaved similarly to unlabeled native protein with respect to PAI-1 binding and stabilization, indicating that the probes did not disrupt elements
essential for either activity. Fluorescence studies showed that
PAI-1 binding was associated with a 15% quench in
HOCGO-VN fluorescence. When PAI-1 was bound to vitronectin, the Stern-Volmer plots for iodide quenching were identical
to those of HOCGO-VN in the absence of PAI-1. The evidence
that PAI-1 does not affect the susceptibility of the probe to
iodide quenching indicates that alterations in coumarin fluorescence upon PAI-1 binding are not the result of direct PAI-1
interactions with the probe. Rather, the binding of PAI-1 results in an altered conformation at the heparin-binding site on
vitronectin. The PAI-1-induced conformational change within
the heparin-binding region of vitronectin is also detected by
enhanced binding of PAI-1zvitronectin complexes over vitronectin alone to surface-immobilized heparin.
Heparin and PAI-1 Do Not Share a Binding Determinant in
Vitronectin—Three lines of evidence from this work dispute the
concept that PAI-1 and heparin share a binding determinant in
vitronectin. Modification of arginines in vitronectin with hydroxycoumarin glyoxal weakens heparin binding but does not
affect PAI-1 binding or stabilization. Fluorescent probes,
thought to be incorporated into the heparin-binding domain of
vitronectin, are not protected from iodide quenching when
HOCGO-VN is bound to PAI-1. Heparin and PAI-1 do not
compete for binding to vitronectin. If heparin and PAI-1 did
share a binding determinant in vitronectin, modifications of
residues in the sequence would be expected to weaken vitronectin binding to both macromolecules. HOCGO-VN would then be
expected to have a weakened affinity for PAI-1. Only affinity
for heparin is affected by the modification, while interactions
with PAI-1 are unperturbed.
Second, it could be argued that PAI-1 and heparin share a
binding determinant but that specific residues critical for interaction within that determinant are different for the serpin
and the glycosaminoglycan. The iodide quenching data indicate
that the heparin-binding residues that undergo modification
are not located near the PAI-1-binding sites. Otherwise, the
modified residues would be expected to have decreased solvent
exposure in the presence of PAI-1.
Finally, data from several competition experiments further
dispute the possibility that heparin and PAI-1 share a binding
determinant. PAI-1 bound to vitronectin-coated microtiter
plates somewhat more effectively in the presence of heparin.
Likewise, vitronectin complexed with PAI-1 bound heparincoated plates somewhat more effectively than vitronectin
alone. These observations contradict a previous report by Kost
et al. (26) in which high concentrations of heparin prevented
PAI-1 binding to immobilized vitronectin. However, a different
report by the same group failed to demonstrate competition
between heparin and PAI-1 for binding a CNBr fragment of
vitronectin (30).
The results from competition experiments described in this
document provide evidence that PAI-1 and heparin do not
share a common binding site on vitronectin. Otherwise, at the
saturating concentrations used, heparin and PAI-1 would be
expected to compete for vitronectin binding. The observation
that each of the two molecules increases the binding affinity of
vitronectin for the other could have several interpretations. 1)
Because both vitronectin and PAI-1 bind heparin, the glyco-

saminoglycan could serve as a template for their interaction,
providing a common surface on which they both interact. This
function has been attributed to heparin in the interaction between thrombin and antithrombin (67–70). 2) Since heparin
bound to immobilized vitronectin could provide additional
binding sites for PAI-1, more PAI-1 may bind in the well. 3) As
both heparin and PAI-1 have been demonstrated to alter the
conformation of vitronectin, the phenomenon could be an example of allostery, where binding of one of the macromolecules
results in conformational changes that increase the affinity of
vitronectin for the other.
Concluding Remarks—The goal of these studies was to investigate conformational changes in vitronectin and PAI-1 using fluorescently labeled proteins. The probes incorporated into
the proteins have provided useful information about the conformational changes that occur in the molecules as a result of
their interaction. The data obtained with NBD PAI-1 demonstrate that binding native but not multimeric vitronectin alters
the conformation of the reactive center loop of PAI-1. Changes
in the fluorescence of probes incorporated into the heparinbinding domain of vitronectin indicate that the heparin-binding region is not an important binding determinant for PAI-1.
Rather, this region experiences a conformational change when
vitronectin and PAI-1 interact. Furthermore, the fluorescently
labeled proteins serve as valuable tools for continued investigation of mechanistic aspects of the PAI-1zvitronectin interaction.
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